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Bedwetting is a very common problem.  Up to 15% of 5-year-olds wet their beds more
than 3 times per week.  Among the general public considerable ignorance remains
about the causes of bedwetting and the fact that effective treatment is available.
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This article presents an approach to bedwetting that will help the general practi-
tioner to recognise benign enuresis, and to treat children suffering from it with
confidence and success.
DEFINITIONS
The exact nature of the child’s bedwetting needs to be carefully elucidated, mak-
ing a clear distinction between enuresis and incontinence: 
• Enuresis can be defined as the persistent, involuntary voiding of a normal
urine volume during sleep, beyond the age of expected continence (i.e. 5
years).1
• Incontinence can be defined as the involuntary voiding of small amounts of
urine during wakefulness or sleep.
CLASSIFICATION OF BEDWETTING
Enuresis can be classified according to its course, the time of its occurrence, or
its aetiology.  
• Course
• Primary/persistent (never been dry).
• Secondary/regressive (previous dryness achieved for a period of at least 6
months).
• Time of occurrence
• Nocturnal (mono-/polysymptomatic).
Monosymptomatic nocturnal enuresis (MNE): No other symptoms.
Polysymptomatic nocturnal enuresis (PNE): Abnormal voiding pattern dur-
ing wakefulness.




PATHOPHYSIOLOGICAL MECHANISMS OF BEDWETTING (FIG. 1)
Non-organic causes 
• Maturational delay 
• inadequate arousal response to bladder fullness (suppressed reticular acti-
vation system — deep sleeper) 
• abnormally high nocturnal urine production (inadequate nocturnal increase
of antidiuretic hormone (ADH) secretion) 
• Small functional bladder capa-
city (spontaneous voiding occurs
when this is exceeded).
• Psychological disturbance (second-
ary enuresis).





• structural abnormalities.  




– CNS injury/cerebral palsy
– CNS tumours
– epilepsy





– neurogenic bladder (flaccid
type).
• Endocrine
• diabetes mellitus (insulin defi-
ciency)
• diabetes insipidus (vasopressin
deficiency).
EPIDEMIOLOGY
• 15% of 5-year-olds wet their
beds 
• 7% of 10-year-olds wet their
beds 
• 1% of 15-year-olds wet their
beds. 
Spontaneous resolution of enuresis
occurs at a rate of 15% per year.
Enuresis is more common in:
• boys (5:3 girls)
• large families
• poor socio-economic circum-
stances.
Incidence of bedwetting by aetiology:
• MNE — 85%
• PNE — 10%




Enquire about the following:
• Previous period(s) of dryness, i.e.
distinguish between primary and
secondary enuresis. Primary enure-
sis, for all practical purposes, is
never caused by psychological fac-
tors other than developmental
delay.  Psychological disorders may
develop due to persistent enuresis.
Secondary enuresis could be due
to psychological or pathological
factors. 
• Daytime wetting/voiding abnormal-
ities/frequency of micturition (the
presence of which rules out MNE).2
• Urinary tract infections (UTIs) cause
enuresis by rendering the bladder
irritable and unstable.  UTIs may
be indicative of an underlying struc-
tural or functional disorder). 
• Urinary stream (weak stream sug-
gests possible structural or function-
al obstruction).
• Constipation/faecal incontinence/
encopresis (dysfunctional bowel is
often associated with dysfunctional
detrusor and hence abnormalities
of voiding).
• Renal disease (polyuria causes bed-
wetting). 
• Polydipsia/polyuria (may indicate
diabetes mellitus or diabetes
insipidus). 
• Neurological deficits: Developmen-
tal delay/CNS disorder/epilepsy/
abnormal gait (all suggesting a
possible central or peripheral disor-
der of bladder control).
• Sleep disturbance, e.g. obstructive
apnoea (excessive fatigue). 
• Psychological disturbances, includ-
ing attitude of patient and parents
(leading to regressional behaviour
and secondary enuresis). 
• Abnormalities in toilet training his-
tory (possibly causing a psychologi-
cal upset). 
• Family history of enuresis or renal
disease (enuresis is frequently famil-
ial). 
• Previous treatment or medication.
Examination 
• General health (including growth
centiles and blood pressure).
• Gastrointestinal system (faecal
loading, incontinence).
• Urinary system (kidneys, bladder
and genitalia).
• Neurological examination:
• focal signs in legs (power, tone,
tendon reflexes, sensation)
• gross motor function — hopping
on one leg 
• genitalia (cremasteric reflex in
boys) 
• anal sensation and tone 
• sacral abnormalities —
dimple/tuft of hair.
Special investigations 
• Urine dipstick — including specific
gravity — on first morning urine.
• Urine microscopy and culture (if
dipstick test is abnormal or other-
wise indicated).
Recognising benign enuresis
• No symptoms or signs of any
underlying disease.




Is it  MNE or not?
If  ‘Yes’: Can be managed by general
practitioner.
If  ‘No’: Refer to a paediatrician, urol-
ogist or paediatric nephrologist.
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MANAGEMENT OF MNE
Explanation of maturational delay:
• inadequate arousal response to
bladder fullness 
• inadequate increase in nocturnal
ADH production  
• small functional bladder capacity.
Reassurance: Quote epidemiological
statistics (see above). Reaffirm that no
disease is present.
General measures
These lead to some decrease in wet
nights in up to 70% of patients with
MNE. 
• Quiet bed-time routine.
• Restrict fluid 1 - 2 hours before
bedtime.
• Avoid caffeinated and citrus bever-
ages, chocolate (cause polyuria).
• Bladder voiding before retiring.
• Waking to urinate at regular inter-
vals during the night (‘lifting’).
• No punishment or belittlement.
• Protection of bedding.
• Night light (to alleviate fear of
going to the toilet in the dark).
Specific measures 
• Record dry nights (only dry nights
are marked and celebrated on a star
chart) 
• Motivation (reward dry nights and
self-arousal to go to toilet).
• Dry bed training — regular noctur-
nal wakening to void at progressive-
ly later times or increasing intervals.2
• Medication (not before 6 years of
age) 
• DDAVP (desmopressin – ADH
analogue)1
• imipramine (Tofranil — anti-
depressant that facilitates waken-
ing, increases ADH release and
increases bladder capacity).
• Oxybutynin (Ditropan – only
given if daytime frequency occurs).
• Alarm therapy (co-operation being
rewarded), which includes the fol-
lowing:
• arousal training (learning to wake
up to alarm) 
• cleanliness training (learning to
clean up after a wet night) 
• over-learning (giving extra fluid at
night to induce bladder fullness
and to test wakening response).
• Bladder training — delaying voiding
for increasing periods when daytime
frequency symptoms are present.
Only possible in older co-operative
children.
N.B. Bladder antispasmodics, e.g.  oxy-
butynin (Ditropan), are inappropriate for
the treatment of MNE.
INDICATIONS FOR VARIOUS
TREATMENT MODALITIES
When to consider alarm
therapy
• Highly motivated child and parents
(obsessive-compulsivity is benefi-
cial!).
• No daytime incontinence.
• Wetting occurs later in the course of
the night.
• Relapse after previously successful
alarm therapy.
Advantages
• Moderate cost (R500 - R700).
• High success rate if used correctly
(up to 70% long-term remission).3
Disadvantages
• High fall-off rate.
• Not suitable for disorganised or
dysfunctional families.3
When to consider DDAVP
• Primary enuresis in the older child
without daytime frequency.
• Wetting less than 3 times per week
and later in the course of the night
(> 4 hours after going to bed).
• High nocturnal urine volume (noc-
turnal volume > 75% of daytime
volume, calculated as urine produc-
tion per hour).  The day-night urine
production ratio can be determined
by recording the time and volume
of each void over 24 hours.
Nappies must be worn overnight
and their wet weight recorded.




• Safe. The only danger is hypona-
traemia if excessive water is ingest-
ed overnight.
• Very few side-effects (nasal symp-
toms when using nasal spray,
headache, abdominal pain).
• Rapid response within 48 hours (by
the second dose).
• Can be used intermittently (e.g. for
camps and sleepovers, starting the
night before).2
Disadvantages
• High cost (the better medical aids
only pay for 4 months of DDAVP
therapy).
Enuresis can be defined as
the persistent, involuntary
voiding of a normal urine
volume during sleep,
beyond the age of expect-
ed continence (i.e. 5
years).
Primary enuresis, for all
practical purposes, is never
caused by psychological




are inappropriate for the
treatment of MNE.
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BENIGN ENURESIS
Primary or secondary





Polyuric (better response to DDAVP)
PATHOLOGICAL ENURESIS
Possible causes


















Nasal spray 20 - 40 µg nocte
Tablets 0.2 - 0.4 mg nocte
• Imipramine






• Continue for ≥ 3 months
• Consider DDAVP for
special occasions
• Continue for 3 months






Fig. 2.  Algorithm for management of enuresis.
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• High relapse rate after discontinua-
tion (but less than imipramine).
Dosage
• Nasal spray (10 µg/spray): 20 - 40
µg on retiring
• Tablets (100 µg/tab): 200 - 400 µg,
1 - 2 hours after supper.
When to consider imipramine
• If the cost of treatment is a prob-
lem.
• In the presence of significant psy-
chological factors.
• When there is evidence of a small
functional bladder capacity.





• Response time up to 14 days.
• Side-effects include irritability, dry
mouth, headache, anorexia, consti-
pation.
• Severe (irreversible) cardiotoxicity
in overdose (beware of younger
siblings).
• Very high relapse rate after discon-
tinuation.
Dosage
• Tablets are available in 10 mg or
25 mg strengths.
• Start with 1 mg/kg at suppertime,
increase to a maximum of 2.5
mg/kg nocte. Some patients
respond better to divided doses:
1/3 mane and 2/3 nocte or simply
1/2 mane 1/2 nocte.
When to consider
oxybutynin
• Small functional bladder capacity
or mildly dysfunctional detrusor.
• Daytime frequency, urgency and
urge incontinence.
• Multiple wetting episodes per night.
• Variable wetting volume (size of
wet patch).




• Anticholinergic side-effects, e.g.
dry mouth, constipation, blurred
vision.
• Ineffective for MNE.
Dosage
• 2.5 - 10 mg at supper time (0.15 -
0.2 mg/kg).
• Sometimes 2 - 3 divided doses are
helpful.
Fig. 2. gives an algorithm for manage-
ment of enuresis.
References available on request.
Fifteen per cent of 5-year-olds, 7% of
10-year-olds and 1% of 15-year-olds
wet their beds.
The exact nature of a child’s bedwet-
ting needs to be carefully elucidated,
making a clear distinction between
enuresis and incontinence.
Enuresis can be defined as the per-
sistent, involuntary voiding of a nor-
mal urine volume during sleep,
beyond the age of expected conti-
nence (i.e. 5 years).
The most common cause of bedwet-
ting is benign enuresis.
Benign enuresis (monosymptomatic
nocturnal enuresis) is caused by a
combination of (i) inadequate arousal
response to bladder fullness; (ii) inad-
equate increase in nocturnal ADH
production; and (iii) a small function-
al bladder capacity.
Benign enuresis is recognised by (i)
the absence of symptoms or signs of
any underlying disease; (ii) wetting
that occurs exclusively during sleep;
and (iii) normal urinalysis.
Primary enuresis is almost never
caused by psychological problems.
The most common causes of second-
ary enuresis (relapse after 6 months
of dryness) are urinary tract infection
and psychological disturbance.
The most effective treatment for
benign enuresis is alarm therapy.
The most effective medication for
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Fig. 1. Pathophysiology of mono-
symptomatic nocturnal enuresis:
Maturational delay (1 — suppressed
reticular activation system; 2 —
inadequate nocturnal increase in
ADH secretion; 3 — small functional
bladder capacity).
